Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.

• Status: Recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The clinical trial is designed to evaluate the efficacy of bicyclol for patients with antineoplastic drug-induced liver injury and investigate factors effecting the therapeutic outcome.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Criteria

Inclusion Criteria:

1. The acute liver injury caused by anti-tumor drugs

2. The RUCAM assessment scale ≥6

3. The liver injury must in the acute phase

4. Must be treated with bicyclol tablets

5. Must sign informed consent -

Exclusion Criteria:

1. This acute liver injury caused by non-anti-tumor drugs

2. Pregnant women

3. Lactating women

4. Childbearing age women are plan to conceive